Sionna Therapeutics Financials
This page shows Sionna Therapeutics (SION) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025 shows a research-heavy, asset-light cash-burn model whose balance-sheet repair came from financing, not operating self-funding.
Over the last two years, free cash flow tracked operating cash flow very closely, so cash use came mainly from ongoing operations rather than from large equipment purchases or other investment buildout. Financing cash inflow of$205.7M helped move shareholders’ equity from-$163.7M in deficit to a strong positive base, which means the company repaired solvency without yet changing its underlying cash-burning operating pattern.
The expense mix is scientific rather than commercial: R&D was
Near-term liquidity looks ample because current assets were
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Sionna Therapeutics's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Sionna Therapeutics carries a low D/E ratio of 0.06, meaning only $0.06 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 20.61, Sionna Therapeutics holds $20.61 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Sionna Therapeutics generates a -24.5% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100.
Sionna Therapeutics passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Sionna Therapeutics generates $0.88 in operating cash flow (-$66.3M OCF vs -$75.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Sionna Therapeutics's EBITDA was -$88.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 26.4% from the prior year.
Sionna Therapeutics reported -$75.3M in net income in fiscal year 2025. This represents a decrease of 22.0% from the prior year.
Sionna Therapeutics earned $-1.88 per diluted share (EPS) in fiscal year 2025. This represents an increase of 88.2% from the prior year.
Cash & Balance Sheet
Sionna Therapeutics generated -$66.7M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 26.2% from the prior year.
Sionna Therapeutics held $58.5M in cash against $0 in long-term debt as of fiscal year 2025.
Sionna Therapeutics had 45M shares outstanding in fiscal year 2025. This represents an increase of 847.0% from the prior year.
Margins & Returns
Sionna Therapeutics's ROE was -24.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Capital Allocation
Sionna Therapeutics invested $60.3M in research and development in fiscal year 2025. This represents an increase of 5.2% from the prior year.
Sionna Therapeutics invested $377K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 1296.3% from the prior year.
SION Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $19.0M | N/A | $16.0M+4.3% | $15.4M+12.5% | $13.7M | N/A | $24.6M+198.6% | $8.2M |
| SG&A Expenses | $10.6M | N/A | $7.8M+19.0% | $6.5M+8.9% | $6.0M | N/A | $3.4M+11.2% | $3.1M |
| Operating Income | -$29.6M | N/A | -$23.8M-8.7% | -$21.9M-11.4% | -$19.7M | N/A | -$28.0M-147.8% | -$11.3M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$26.8M | N/A | -$20.3M-12.2% | -$18.1M-9.6% | -$16.5M | N/A | -$25.4M-197.5% | -$8.6M |
| EPS (Diluted) | $-0.60 | N/A | $-0.46-12.2% | $-0.41+33.9% | $-0.62 | N/A | $-5.67-109.2% | $-2.71 |
SION Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $305.0M-6.4% | $326.0M-3.9% | $339.3M-3.6% | $352.0M-4.8% | $369.7M+99.0% | $185.8M | N/A | N/A |
| Current Assets | $221.0M-8.5% | $241.4M-4.3% | $252.3M-5.4% | $266.7M-2.5% | $273.7M+81.3% | $151.0M | N/A | N/A |
| Cash & Equivalents | $63.3M+8.3% | $58.5M+15.0% | $50.8M+24.0% | $41.0M-50.4% | $82.7M+118.8% | $37.8M+5.7% | $35.7M-18.8% | $44.0M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $16.8M-12.0% | $19.1M+8.6% | $17.6M+12.7% | $15.6M-12.8% | $17.9M-94.9% | $349.5M | N/A | N/A |
| Current Liabilities | $9.8M-16.5% | $11.7M+18.9% | $9.9M+30.5% | $7.5M-20.8% | $9.5M-8.6% | $10.4M | N/A | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $288.2M-6.1% | $306.8M-4.6% | $321.7M-4.4% | $336.4M-4.4% | $351.8M+314.9% | -$163.7M-10.2% | -$148.5M-11.0% | -$133.8M |
| Retained Earnings | -$283.1M-10.4% | -$256.4M-8.7% | -$235.9M-9.4% | -$215.6M-9.1% | -$197.6M-9.1% | -$181.1M | N/A | N/A |
SION Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$21.8M-31.4% | -$16.6M-9.2% | -$15.2M+16.1% | -$18.2M-11.5% | -$16.3M-38.3% | -$11.8M+33.4% | -$17.7M-74.3% | -$10.1M |
| Capital Expenditures | $0-100.0% | $204K+134.5% | $87K | $0-100.0% | $86K+218.5% | $27K | $0 | $0 |
| Free Cash Flow | -$21.8M-29.8% | -$16.8M-9.9% | -$15.3M+15.6% | -$18.2M-10.9% | -$16.4M-38.7% | -$11.8M+33.2% | -$17.7M-74.3% | -$10.1M |
| Investing Cash Flow | $24.8M+9.9% | $22.6M-2.2% | $23.1M+199.4% | -$23.2M+83.5% | -$141.2M-1027.2% | $15.2M+46.3% | $10.4M+136.4% | -$28.6M |
| Financing Cash Flow | $1.9M+14.1% | $1.7M-16.0% | $2.0M+732.7% | -$312K-100.2% | $202.4M+14474.2% | -$1.4M-41.4% | -$996K-2721.1% | $38K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
SION Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -9.3% | N/A | -6.3%-0.9pp | -5.4%-0.7pp | -4.7% | N/A | N/A | N/A |
| Return on Assets | -8.8% | N/A | -6.0%-0.9pp | -5.1%-0.7pp | -4.5% | N/A | N/A | N/A |
| Current Ratio | 22.60+2.0 | 20.61-5.0 | 25.61-9.7 | 35.33+6.6 | 28.73+14.2 | 14.49 | N/A | N/A |
| Debt-to-Equity | 0.060.0 | 0.060.0 | 0.050.0 | 0.050.0 | 0.05+2.2 | -2.13 | N/A | N/A |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Sionna Therapeutics profitable?
No, Sionna Therapeutics (SION) reported a net income of -$75.3M in fiscal year 2025.
What is Sionna Therapeutics's EBITDA?
Sionna Therapeutics (SION) had EBITDA of -$88.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Sionna Therapeutics's return on equity (ROE)?
Sionna Therapeutics (SION) has a return on equity of -24.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Sionna Therapeutics's free cash flow?
Sionna Therapeutics (SION) generated -$66.7M in free cash flow during fiscal year 2025. This represents a -26.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Sionna Therapeutics's operating cash flow?
Sionna Therapeutics (SION) generated -$66.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Sionna Therapeutics's total assets?
Sionna Therapeutics (SION) had $326.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Sionna Therapeutics's capital expenditures?
Sionna Therapeutics (SION) invested $377K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Sionna Therapeutics spend on research and development?
Sionna Therapeutics (SION) invested $60.3M in research and development during fiscal year 2025.
What is Sionna Therapeutics's current ratio?
Sionna Therapeutics (SION) had a current ratio of 20.61 as of fiscal year 2025, which is generally considered healthy.
What is Sionna Therapeutics's debt-to-equity ratio?
Sionna Therapeutics (SION) had a debt-to-equity ratio of 0.06 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Sionna Therapeutics's return on assets (ROA)?
Sionna Therapeutics (SION) had a return on assets of -23.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Sionna Therapeutics's cash runway?
Based on fiscal year 2025 data, Sionna Therapeutics (SION) had $58.5M in cash against an annual operating cash burn of $66.3M. This gives an estimated cash runway of approximately 11 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Sionna Therapeutics's Piotroski F-Score?
Sionna Therapeutics (SION) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Sionna Therapeutics's earnings high quality?
Sionna Therapeutics (SION) has an earnings quality ratio of 0.88x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Sionna Therapeutics?
Sionna Therapeutics (SION) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.